Luciferase-Rose Bengal Conjugates for Single Oxygen Generation by Bioluminescence Resonant Energy Transfer

Conjugates of Rose Bengal and Renilla luciferase generated singlet oxygen upon binding with coelenterazine via bioluminescence resonance energy transfer (BRET). Since the applications of conventional PDT have been limited to superficial lesions due to the limited light penetration in tissue, BRET activated PDT which does not require external light illumination may overcome the limitations of conventional PDT.115Ysciescopu

The United States COVID-19 Forecast Hub dataset

Academic researchers, government agencies, industry groups, and individuals have produced forecasts at an unprecedented scale during the COVID-19 pandemic. To leverage these forecasts, the United States Centers for Disease Control and Prevention (CDC) partnered with an academic research lab at the University of Massachusetts Amherst to create the US COVID-19 Forecast Hub. Launched in April 2020, the Forecast Hub is a dataset with point and probabilistic forecasts of incident cases, incident hospitalizations, incident deaths, and cumulative deaths due to COVID-19 at county, state, and national, levels in the United States. Included forecasts represent a variety of modeling approaches, data sources, and assumptions regarding the spread of COVID-19. The goal of this dataset is to establish a standardized and comparable set of short-term forecasts from modeling teams. These data can be used to develop ensemble models, communicate forecasts to the public, create visualizations, compare models, and inform policies regarding COVID-19 mitigation. These open-source data are available via download from GitHub, through an online API, and through R packages

Models of Interconnection in Telecommunications

We proposed and utilized a simple model to review relay interconnection literatures. Without any complications of scale economies and opportunity costs, marginal cost pricing of interconnection charge is optimal. When incumbent sets the interconnection charge, it may or may not foreclose entrants depending upon degree of entrant's efficiency and forms of interconnection charge. When there are opportunity costs for incumbent to interconnect, then opportunity cost should be paid by the entrant according to the efficient component pricing rule. When there are economies of scale, Ramsey pricing comes to rescue. In an extension of Ramsey spirit, the global price caps are suggested. Next, we have reviewed the current status of the two-way access theory. First, a case of collusive retail prices has been presented even when the market competition exists between symmetric networks. In this case, the use of two-part tariffs or price discrimination can help, as they enable firms to compete in market shares without affecting their access payments. Various types of Internet interconnection are presented along with main results by Laffont, Marcus, Rey and Tirole (2001a, b) on the pricing issues of Internet interconnection

Oliot EPCIS: An open-source EPCIS 2.0 system for supply chain transparency

An international standard, GS1 EPCIS, has given data transparency on supply chains and logistics and taken a new turn in the era of the Internet of Things by ratifying the major release of v2.0 in July 2022 with the official support for sensor data and Semantic Web. Oliot EPCIS is an open-source Web information system pursuing full compliance with the data format and service interface requirements ratified in the standard. The paper presents challenges towards a highly scalable EPCIS system and how the proposed system resolves the challenges. We share the quantitative and qualitative evaluation compared to existing open sources

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

MET amplification is a frequently observed genomic aberration in solid tumors. We conducted a phase I trial to evaluate dose-limiting toxicity (DLT) and recommended phase II dose (RP2D) for the combination therapy. The following dose levels were tested in this single-arm phase I study: docetaxel as an intravenous infusion over 1 hour at 60 mg/m2 once every 3 weeks of a 21-day schedule plus savolitinib (level 1, 200 mg qd; level 2, 400 mg qd; level 3, 600 mg qd; level 4800 mg qd). In total, there were 17 patients enrolled on to this study [7 gastric cancer (GC) patients, 5 melanoma patients, 3 sarcoma patients, and 2 rectal cancer patients]. Most of the patients (14 of 17) were heavily pretreated (≥third line or greater lines of treatment). For the first 3 cohorts (200 mg savolitinib + docetaxel 60 mg/m2, 400 mg savolitinib + docetaxel 60 mg/m2, 600 mg savolitinib + docetaxel 60 mg/m2), there were no DLTs. In the fourth dose cohort (800 mg savolitinib + docetaxel 60 mg/m2), one DLT occurred with generalized edema grade 3 that required intensive management. One GC patient with both MET overexpression (3+) and MET amplification (MET/CEP7 ratio, 7.3) achieved a durable partial response for 297 days, and another MET-amplified GC patient (MET/CEP7 ratio, 7.6) achieved stable disease for 86 days. Due to the higher incidence of G4 neutropenia in cohort 4 (800 mg), we recommend savolitinib 600 mg qd in combination with docetaxel 60 mg/m2 as the RP2D for phase II trial. The combination therapy demonstrated a very promising antitumor activity with durable responses in MET amplified GC patients